Competitive and efficient., Corporate Finance

Assume that there are two firms, firm A and firm B. The firms have identical present values at £10,000 and an identical future value profile as given in the picture below. The probabilities of the two different future values are given on the branches below. The required rate of return on a risk free asset is 5%. There are no taxes at the present time and no synergies between the two firms of any type. There is one difference between the two firms which is that firm B has the same profile as firm A except that it is levered with a £5000 nominal debt that has to be repaid in the next period (this is a two period model). Assume that markets are competitive and efficient.

The present value for firm A = £10,000 = the present value for firm B = £10,000

2401_corporate finance.png

a) What is the expected future value for firm A?

b) What is the expected future value for firm B?

c) Assume that 1000 shares have been issued by firm A. What is the price of one share?

d) Is the debt for firm B risky or riskless?

e) What is the present value of equity for firm B? (hint - you need to value a corporate bond - see p.653 of Brealey and Myers, 2009)

Now consider that the two firms merge to become firm AB.

f) What are the future values for the new merged firm AB?

g) What is the expected future value for the firm AB?

h) What is the required rate of return on the assets for the firm AB?

i) Is the debt for firm AB risky or riskless?

j) Did the merger relieve financial distress? Explain your answer.

Now, start over again with firm A and B as before, but let us now assume that we have corporate taxes and that the interest payments on debt are tax deductible. The corporate tax rate, Tc, is equal to 0.3. As at the beginning of the exercise, the firms are not yet merged. Assume that the present value for the tax shields for firm B is £1,300.

k) Are the tax shields for firm B risky or riskless?

l) What is the present value for firm B?

Now consider that, in this new environment with corporate taxes (as described above), the firms A and B merge to become firm AB.

m) What is the total present value of the merged firm (with corporate taxes as described above)?

n) What is the net gain (if any) of the merger to firm A's shareholders?

o) What conclusions do you reach from your answers?

Posted Date: 2/22/2013 2:26:11 AM | Location : United States

Related Discussions:- Competitive and efficient., Assignment Help, Ask Question on Competitive and efficient., Get Answer, Expert's Help, Competitive and efficient. Discussions

Write discussion on Competitive and efficient.
Your posts are moderated
Related Questions
Net present value of this project: The following I/S is based on the information associated with a new project. Answer the questions. Projected Income Statem

You are a ceo of a sotware firm that has limited access to debt equity markets. The average return on last year projects is 28 % . and cost of capital is 12%. would npv pr Irr be

Hydra Multinational is a vast conglomerate firm involved in a wide array of business ventures ranging from satellite radio to cat food.  One of its many divisions, a restaurant cha

Question: a) NLTF= Mur150m; WCN= 146m; Liquidity= 14m b) Balance Sheet has been solidified by loan from the Holding Company. Had the loan not been prov

Preview division divides M proportional to preview demand, i.e., each SKU n 2N gets fraction This method is included because it is used by the case company, in combination

I need to know about corporate financial analysis

Fashion products in general are characterized by high demand uncertainty, high stockout costs and a high risk of obsolescence (Lee, 2002). Although the speci?c mail order company t

Risk means balancing between profitability and long-term growth. If a company looks at short-term goals, it may go in for profit maximization but it will find it difficult to susta

Pfizer Incorporated has 2 million shares of common stock, selling at $18 each. The β of the stock is 1.5, T-bill rate is 6%, and the expected return on the market is 12%. Pfizer al